Influence of TCF7L2 gene variants on the therapeutic response to the dipeptidylpeptidase-4 inhibitor linagliptin
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Influence of TCF7L2 gene variants on the therapeutic response to the dipeptidylpeptidase-4 inhibitor linagliptin
Authors
Keywords
Clinical science, DPP-4 inhibitor, Genetics of type 2 diabetes, Human, Linagliptin, Oral pharmacological agents, Pharmacogenomics, <em class=EmphasisTypeItalic >TCF7L2</em>
Journal
DIABETOLOGIA
Volume 57, Issue 9, Pages 1869-1875
Publisher
Springer Nature
Online
2014-06-06
DOI
10.1007/s00125-014-3276-y
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The Role of Endogenous Incretin Secretion as Amplifier of Glucose-Stimulated Insulin Secretion in Healthy Subjects and Patients With Type 2 Diabetes
- (2012) H. J. Woerle et al. DIABETES
- The oral DPP-4 inhibitor linagliptin significantly lowers HbA1c after 4 weeks of treatment in patients with type 2 diabetes mellitus
- (2011) T. Forst et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study
- (2011) R. Gomis et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of linagliptin in persons with Type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study1
- (2011) D. R. Owens et al. DIABETIC MEDICINE
- Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study
- (2010) M.-R. Taskinen et al. DIABETES OBESITY & METABOLISM
- Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial
- (2010) S. Del Prato et al. DIABETES OBESITY & METABOLISM
- New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk
- (2010) Josée Dupuis et al. NATURE GENETICS
- Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis
- (2010) Benjamin F Voight et al. NATURE GENETICS
- Association between TCF7L2gene polymorphisms and susceptibility to Type 2 Diabetes Mellitus: a large Human Genome Epidemiology (HuGE) review and meta-analysis
- (2009) Yu Tong et al. BMC Medical Genetics
- The T allele of rs7903146 TCF7L2 is associated with impaired insulinotropic action of incretin hormones, reduced 24 h profiles of plasma insulin and glucagon, and increased hepatic glucose production in young healthy men
- (2009) K. Pilgaard et al. DIABETOLOGIA
- Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes
- (2009) Carolyn F Deacon et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Decreased TCF7L2 protein levels in type 2 diabetes mellitus correlate with downregulation of GIP- and GLP-1 receptors and impaired beta-cell function
- (2009) Luan Shu et al. HUMAN MOLECULAR GENETICS
- The WNT signalling pathway and diabetes mellitus
- (2008) T. Jin DIABETOLOGIA
- Cross Talk between the Insulin and Wnt Signaling Pathways: Evidence from Intestinal Endocrine L Cells
- (2008) Fenghua Yi et al. ENDOCRINOLOGY
- Minireview: The Wnt Signaling Pathway Effector TCF7L2 and Type 2 Diabetes Mellitus
- (2008) Tianru Jin et al. MOLECULAR ENDOCRINOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search